Eurogin is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa

Registration will be back soon. Thank you for your patience!

Open main menu

Program Topics (provional)

Provisionnal list of sessions

DOWNLOAD PROGRAM TOPICS

Screening

The European Guidelines for quality assurance in cervical cancer screening
Risk based screening
European initiatives for vaccination against HPV and risk-based HPV screening
Quality assurance measures in countries that switched to HPV primary screening

Self-sampling

HPV-testing on self-samples
Towards standardization of HPV self-collected samples
PAVE results (core NCI)
Evidence on the comparability of self-sampling VS provider-sampling for HPV testing
HPV self-sampling among transgender and gender diverse individuals
The utility of urine for improved cervical cancer prevention
Enhancing cervical cancer screening by improving attendance and self-sampling

Vaccines

Strategies for faster cervical cancer elimination
Cervical cancer accelerated elimination policies
Single dose HPV vaccination: updates across research domains
Head-to-head comparison of vaccines and vaccination strategies
Long‐term follow‐up and impact studies for HPV vaccines

Testing

HPV-test validation
Global HPV laboratory network
Next generation analysis and bioinformatics
Validation of HPV tests for less established indications

Management

HPV and reproductive health
HPV among children
Recurrence of HSIL after treatment
Colposcopy: discussion on challenging cases
HPV in older women: epidemiology, screening and management
Targeted therapies of HPV related cancers

Methylation

Clinical indications for DNA methylation analysis for cervical cancer prevention
Structural and social factors that impact HPV driven cancers
Evolving patterns in HPV-driven cancers

Circulating HPV DNA

Circulating HPV DNA for early diagnosis and clinical management of HPV-related cancers

Low- and middle-income countries

Global inequalities in cervical cancer prevention: are we currently on the path to cervical cancer elimination?
Real-word experience of the implementation of a screen-triage-treat strategy in LMICs
Cervical cancer in sub-Saharan Africa

Special populations

Cervical cancer control among migrants
HPV vaccination and cervical cancer screening among special populations
Cervical cancer screening in homeless women
Prevention of HPV-associated malignancies in disabled populations
Cervical cancer in migrants
Cervical cancer screening in the trans and non-binary community
HPV driven cancer in immunosuppressed populations

Advocacy

Public advocacy and awareness campaigns to address barriers in HPV-associated cancer prevention

Frontier

Global evidence on HPV involvement in human malignancies at specified non-genital sites

Carcinogenesis

Update on anogenital carcinogenesis